Rodman & Renshaw's Raghuram Selvaraju reiterated his Buy position on Synergy Pharmaceuticals Inc (NASDAQ: SGYP) with a price target of $15.00. The rating reiteration comes after further Plecanatide Phase 3 data was reported, showing positive results.
The new data "emphasizes what we view as the drug's strong likelihood of approval early next year," said Selvaraju. Due to further "top-line data release from two ongoing Phase 3 trials of plecanatide" later this year, the analyst believed the price is likely to rise from $3.26 to $15.00 over the next twelve months.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Selvaraju did acknowledge three significant risks to the company, which include:
- Plecanatide failure in clinical trials
- Failure of plecanatide to secure approval
- "Variations in market size, penetration and pricing vs. our model estimates"
Despite Selvaraju's positive outlook for the company, the analyst estimates 2017 EPS to be $(0.29).
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.